BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25616352)

  • 1. Predictors of sentinel lymph node status in cutaneous melanoma: a classification and regression tree analysis.
    Tejera-Vaquerizo A; Martín-Cuevas P; Gallego E; Herrera-Acosta E; Traves V; Herrera-Ceballos E; Nagore E
    Actas Dermosifiliogr; 2015 Apr; 106(3):208-18. PubMed ID: 25616352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sentinel lymph node status in melanoma: prognostic value in a tertiary hospital and correlation with mitotic activity.
    Mahiques Santos L; Oliver Martinez V; Alegre de Miquel V
    Actas Dermosifiliogr; 2014; 105(1):60-8. PubMed ID: 24021663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.
    Azimi F; Scolyer RA; Rumcheva P; Moncrieff M; Murali R; McCarthy SW; Saw RP; Thompson JF
    J Clin Oncol; 2012 Jul; 30(21):2678-83. PubMed ID: 22711850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma.
    Tejera-Vaquerizo A; Nagore E; Puig S; Robert C; Saiag P; Martín-Cuevas P; Gallego E; Herrera-Acosta E; Aguilera J; Malvehy J; Carrera C; Cavalcanti A; Rull R; Vilalta-Solsona A; Lannoy E; Boutros C; Benannoune N; Tomasic G; Aegerte P; Vidal-Sicart S; Palou J; Alos LL; Requena C; Traves V; Pla Á; Bolumar I; Soriano V; Guillén C; Herrera-Ceballos E
    Eur J Cancer; 2015 Sep; 51(13):1780-93. PubMed ID: 26072362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma.
    Wagner JD; Gordon MS; Chuang TY; Coleman JJ; Hayes JT; Jung SH; Love C
    Cancer; 2000 Jul; 89(2):453-62. PubMed ID: 10918179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas.
    Wat H; Senthilselvan A; Salopek TG
    J Am Acad Dermatol; 2016 Jan; 74(1):94-101. PubMed ID: 26542815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
    Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
    Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
    Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
    Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.
    Han D; Zager JS; Shyr Y; Chen H; Berry LD; Iyengar S; Djulbegovic M; Weber JL; Marzban SS; Sondak VK; Messina JL; Vetto JT; White RL; Pockaj B; Mozzillo N; Charney KJ; Avisar E; Krouse R; Kashani-Sabet M; Leong SP
    J Clin Oncol; 2013 Dec; 31(35):4387-93. PubMed ID: 24190111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma.
    Mraz-Gernhard S; Sagebiel RW; Kashani-Sabet M; Miller JR; Leong SP
    Arch Dermatol; 1998 Aug; 134(8):983-7. PubMed ID: 9722728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Mitotic Rate Predicts Sentinel Lymph Node Involvement in Thin Melanomas.
    Skochdopole AJ; Kutlu OC; Engelhardt KE; Lancaster WP; Abbott AM; Camp ER
    J Surg Res; 2020 Dec; 256():198-205. PubMed ID: 32711176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.
    Kruper LL; Spitz FR; Czerniecki BJ; Fraker DL; Blackwood-Chirchir A; Ming ME; Elder DE; Elenitsas R; Guerry D; Gimotty PA
    Cancer; 2006 Nov; 107(10):2436-45. PubMed ID: 17058288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is mitotic rate still useful in the management of patients with thin melanoma?
    Tejera-Vaquerizo A; Pérez-Cabello G; Marínez-Leborans L; Gallego E; Oliver-Martínez V; Martín-Cuevas P; Arias-Santiago S; Aneiros-Fernández J; Herrera-Acosta E; Traves V; Herrera-Ceballos E; Nagore E
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):2025-2029. PubMed ID: 28750139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breslow thickness, clark index and ulceration are associated with sentinel lymph node metastasis in melanoma patients: a cohort analysis of 612 patients.
    Munsch C; Lauwers-Cances V; Lamant L; Gentil C; Rochaix P; Garrido I; Lopez R; Chevreau C; Paul C; Meyer N
    Dermatology; 2014; 229(3):183-9. PubMed ID: 25171688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.
    Paek SC; Griffith KA; Johnson TM; Sondak VK; Wong SL; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
    Cancer; 2007 Jan; 109(1):100-8. PubMed ID: 17146784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
    Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
    Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel node biopsy in thin and thick melanoma.
    Mozzillo N; Pennacchioli E; Gandini S; Caracò C; Crispo A; Botti G; Lastoria S; Barberis M; Verrecchia F; Testori A
    Ann Surg Oncol; 2013 Aug; 20(8):2780-6. PubMed ID: 23720068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
    Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
    Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.